Macroautophagy is a cellular quality-control process that degrades proteins, protein
aggregates and damaged organelles. Autophagy plays a fundamental role in cancer where …

Pancreatic ductal adenocarcinomas are distinguished by their robust desmoplasia, or
fibroinflammatory response. Dominated by non-malignant cells, the mutated epithelium must …

There is a need to develop effective therapies for pancreatic ductal adenocarcinoma (PDA),
a highly lethal malignancy with increasing incidence and poor prognosis. Although targeting …

Pancreatic ductal adenocarcinoma (PDAC) cells use glutamine (Gln) to support proliferation
and redox balance. Early attempts to inhibit Gln metabolism using glutaminase inhibitors …

Pancreatic ductal adenocarcinoma (PDA) is a lethal disease notoriously resistant to
therapy,. This is mediated in part by a complex tumour microenvironment, low vascularity …

Pancreatic ductal adenocarcinoma (PDAC) cells maintain a high level of autophagy,
allowing them to thrive in an austere microenvironment. However, the processes through …

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related morbidity
and mortality in the western world, with limited therapeutic strategies and dismal long-term …

Mitochondrial glutamate-oxaloacetate transaminase 2 (GOT2) is part of the malateaspartate
shuttle, a mechanism by which cells transfer reducing equivalents from the cytosol to the …

Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, is
characterized by poor treatment response and low survival time. The current clinical …

The mechanisms underlying metabolic adaptation of pancreatic ductal adenocarcinoma
(PDA) cells to pharmacologic inhibition of RAS–MAPK signaling are largely unknown. Using …